If the scientists could very precisely measure the proportions of lutetium and halfnium in moon rocks compared to other ...

Novartis Pharmaceuticals Canada Inc. (Novartis) is pleased to announce that, effective February 1, 2025, Nova Scotia is publicly funding Pluvictotm (lutetium (177Lu) vipivotide tetraxetan ...

Novartis Pharmaceuticals Canada Inc. (Novartis) is pleased to announce that, effective February 1, 2025, Nova Scotia is publicly funding Pluvicto™ (lutetium (177Lu) vipivotide tetraxetan injection), ...

Dr. Jonathan R. Strosberg, discussed results of the CABINET trial evaluating Cabometyx versus placebo in advanced ...

Prince Edward Island (PEI) first detected multinucleate sphere unknown (MSX) ? an oyster disease caused by the Haplosporidium nelsoni parasite. Since that time, the Canadian Food Inspection Agency ...

ITM announces positive Phase 3 results for ITM-11 in neuroendocrine tumours, paving the way for a potential new treatment ...

The poster titled “ Preclinical and Translational Pharmacokinetics of GD2-SADA, a Self-Assembling and Disassembling (SADA) Bispecific Fusion Protein for Pretargeted Radioimmunotherapy (PRIT)” ...

The deal includes an upfront payment of $250m, with the potential for an additional $752.5m in milestone payments.

Ken Herrmann, MD, MBA, from the Universitätsklinikum Essen (Germany), and Johannes Czernin, MD, from the David Geffen School ...

After 20 years of building radioisotope expertise as a manufacturer and supplier, German firm ITM Isotope Technologies is ...

ITM's lutetium-containing therapy extended progression-free survival versus everolimus in patients with a specific kind of ...

Hope is crucial for those of us with chronic lymphocytic leukemia, or any cancer, helping us navigate the disease's ...